Engineering and delivery of therapeutic compositions of freshly isolated cells
AssigneeMaxCyte, Inc.
InventorsLinhong Li, Madhusudan V. Peshwa
Life of this patent
Estimating the term…
Abstract
The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.
Claims21
A method for transiently modifying unstimulated resting peripheral blood mononuclear cells (PBMCs) to express a chimeric receptor on their surfaces comprising:
- (a) isolating resting PBMCs;
- (b) electroloading the PBMCs with an mRNA encoding for a chimeric receptor, whereby the electroloaded PBMCs transiently express the chimeric receptor on their surfaces, and wherein viability of the electroloaded PBMCs, as determined at 1 day after electroloading, is at least 80% when normalized to un-electroporated PBMCs.
A method of treating cancer in a subject comprising:
- (a) obtaining unstimulated resting peripheral blood mononuclear cells (PBMCs);
- (b) electroloading the PBMCs with an mRNA encoding for a chimeric receptor, whereby the electroloaded PBMCs transiently express the chimeric receptor on their surface, and wherein viability of the electroloaded PBMCs, as determined at 1 day after electroloading, is at least 80% when normalized to un-electroporated PBMCs;
- and
- (c) administering the electroloaded PBMCs to the subject to treat cancer in the subject.
Dependencies are inferred from the claim text.